US 12,419,887 B2
Transitioning patients treated for pulmonary arterial hypertension to selexipag
Carol Zhao, Titusville, NJ (US); Johanna Colvin Riesen, Titusville, NJ (US); Gary Arnold Palmer, Titusville, NJ (US); Michael Keating, Fairview, NC (US); Brian Hartline, San Diego, CA (US); Wade Benton, Redwood City, CA (US); Camelia Dumitrescu, San Francisco, CA (US); and Mehul Bipinchandra Shah, Titusville, NJ (US)
Assigned to Actelion Pharmaceuticals Ltd., Allschwil (CH)
Appl. No. 17/612,014
Filed by ACTELION PHARMACEUTICALS LTD, Allschwil (CH)
PCT Filed May 20, 2020, PCT No. PCT/EP2020/064089
§ 371(c)(1), (2) Date Nov. 17, 2021,
PCT Pub. No. WO2020/234361, PCT Pub. Date Nov. 26, 2020.
Claims priority of provisional application 62/850,792, filed on May 21, 2019.
Prior Publication US 2022/0257594 A1, Aug. 18, 2022
Int. Cl. A61K 31/4965 (2006.01); A61K 45/06 (2006.01); A61P 9/12 (2006.01)
CPC A61K 31/4965 (2013.01) [A61K 45/06 (2013.01); A61P 9/12 (2018.01)] 5 Claims
OG exemplary drawing
 
1. A method of transitioning a patient being treated for pulmonary arterial hypertension with an oral non-selexipag prostacyclin pathway agent (PPA) to selexipag, comprising administering oral selexipag to the patient at a starting dose and increasing to a highest tolerable maintenance dose that is maintained for greater than about 14 days without change or interruption, wherein the patient was taking the non-selexipag PPA for about 30 or more days at the time of selexipag initiation and stopped the non-selexipag PPA less than about 7 days before the selexipag initiation, or wherein the patient continued taking the non-selexipag PPA at the time of selexipag initiation and subsequently stopped the non-selexipag PPA.